These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35363574)

  • 21. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
    van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
    J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barriers to the use of modern contraceptives and implications for woman-controlled prevention of sexually transmitted infections in Madagascar.
    Randrianasolo B; Swezey T; Van Damme K; Khan MR; Ravelomanana N; Lovaniaina Rabenja N; Raharinivo M; Bell AJ; Jamieson D; ; Behets F
    J Biosoc Sci; 2008 Nov; 40(6):879-93. PubMed ID: 18198005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development.
    Friedland BA; Plagianos M; Savel C; Kallianes V; Martinez C; Begg L; Guthrie KM; Venkatasetty D; Pickett J; Haddad LB
    AIDS Behav; 2023 Jul; 27(7):2190-2204. PubMed ID: 36881183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Contraceptives, HIV, and other sexually transmitted diseases].
    Vandale-Toney S; Conde-González CJ
    Ginecol Obstet Mex; 1995 Jan; 63():40-5. PubMed ID: 7896158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
    Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
    Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
    Chen JH; Wu SC; Shao WQ; Zou MH; Hu J; Cong L; Miao L; Wang C; Dong J; Gao J; Xiao BL
    Contraception; 1998 Jun; 57(6):371-9. PubMed ID: 9693396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hormonal ring. A new contraceptive gains acceptance.
    Hardy EE; Reyes Q; Gomez F; Portes-carrasco R; Faundes A
    IDRC Rep; 1984 Jul; 13(2):11. PubMed ID: 12313242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States.
    Hynes JS; Sales JM; Sheth AN; Lathrop E; Haddad LB
    Contraception; 2018 Mar; 97(3):277-284. PubMed ID: 29055782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.
    Bauermeister JA; Golinkoff JM; Carballo-Diéguez A; Giguere R; López D; Hoesley CJ; Chen BA; Anderson P; Dezzutti CS; Strizki J; Sprinkle C; Heard F; Hall W; Jacobson C; Berthiaume J; Mayo A; Richardson BA; Piper J;
    AIDS Behav; 2020 Feb; 24(2):607-616. PubMed ID: 30877580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theory-based interventions for contraception.
    Lopez LM; Grey TW; Chen M; Tolley EE; Stockton LL
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007249. PubMed ID: 27879980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.
    Roberts ST; Hawley I; Luecke E; Mensch B; Wagner T; Hoesley C; McClure T; Dominguez Islas CP; Piper JM; Liu AY; van der Straten A
    J Womens Health (Larchmt); 2022 Jul; 31(7):1029-1039. PubMed ID: 34665672
    [No Abstract]   [Full Text] [Related]  

  • 32. Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya.
    Wagner LD; Minnis AM; Shea J; Agot K; Ahmed K; van der Straten A
    PLoS One; 2022; 17(5):e0265303. PubMed ID: 35551318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women.
    Kiweewa FM; Brown E; Mishra A; Nair G; Palanee-Phillips T; Mgodi N; Nakabiito C; Chakhtoura N; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2019 Feb; 22(2):e25257. PubMed ID: 30816632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
    PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
    PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women's attitudes to condoms and female-controlled means of protection against HIV and STDs in south-western Uganda.
    Hart GJ; Pool R; Green G; Harrison S; Nyanzi S; Whitworth JA
    AIDS Care; 1999 Dec; 11(6):687-98. PubMed ID: 10716009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD; Browne EN; Gundacker HM; Hawley I; Chen BA; Hoesley C; Scheckter R; Piper J; Singh D; Song M; Liu A; van der Straten A
    PLoS One; 2022; 17(2):e0263664. PubMed ID: 35192655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
    Kestelyn E; Agaba S; Van Nuil JI; Uwineza M; Umulisa MM; Mwambarangwe L; Ndagijimana JC; De Baetselier I; Buyze J; Delvaux T; Crucitti T; Jespers V; van de Wijgert JHHM;
    PLoS One; 2018; 13(6):e0197572. PubMed ID: 29856848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cultural Consensus Modeling to Understand South African Adolescent Girls' Attitudes, Awareness, and Uptake of Dual Protection Strategies.
    Brown JL; Marais L; Sharp C; Cloete J; Lenka M; Rani K; Marime P; Ditlhare I; Moqolo R; Peterson D; Sales JM
    J Adolesc Health; 2020 Dec; 67(6):793-803. PubMed ID: 32800707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
    Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.